“We are honored to welcome these acclaimed experts in oncology to our scientific advisory board,” said
“It is a privilege to work with a talented group of renowned oncology experts to assist
The members of the ALX Oncology SAB include:
Keith Flaherty ,M.D. (Chair) -Dr. Flaherty is a Professor of Medicine atHarvard Medical School and Director of Clinical Research, at theMassachusetts General Hospital Cancer Center . He co-founded and served on the Board of Directors of Loxo Oncology until its acquisition by Eli Lilly and Company. He currently serves on the Board of Directors of Clovis Oncology and Checkmate Pharmaceuticals.Dr. Flaherty has been awarded numerous grants from theNational Cancer Institute , including K23, RO1 and PO1 grants. He is an author of many research articles, abstracts and reviews in the peer-reviewed literature, including three first-author and three senior authorNew England Journal of Medicine papers. He serves as Editor-in-Chief forClinical Cancer Research and on the Board of Directors of theAmerican Association for Cancer Research .Dr. Flaherty holds a B.S. fromYale University and an M.D. fromJohns Hopkins University .Dr. Flaherty trained in internal medicine at Brigham and Women’s Hospital and completed a medical oncology fellowship at theUniversity of Pennsylvania .- Charles M. Baum, M.D., Ph.D. -
Dr. Baum has been President and Chief Executive Officer and Board Member of Mirati Therapeutics for the last eight years. Under his leadership, he transformed Mirati into a world class precision oncology company focused on translating drug discovery and research into novel therapeutics that target the genetic and immunologic drivers of various cancers. Prior to joining Mirati,Dr. Baum was Senior Vice President forBiotherapeutic Clinical Research within Pfizer’sWorldwide Research & Development division and held multiple roles including Vice President and Head ofOncology Development and as Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. He was responsible for the development of Pfizer’s oncology portfolio, including axitinib (Inlyta®), crizotinib (Xalkori®) and the approval of sunitinib (Sutent®). Prior to joining Pfizer,Dr. Baum oversaw the Phase I-IV development of several oncology compounds at Schering-Plough, including temozolomide (Temodar®) for the treatment of patients with advanced brain tumors.Dr. Baum has received research support from theNational Institutes of Health and theAmerican Cancer Society , published more than 50 peer-reviewed manuscripts, and holds a number of patents and patent applications.Dr. Baum currently serves on the board of directors of Immunomedics and BCTG Acquisition Corp.Dr. Baum holds an M.D. and a Ph.D. fromWashington University School of Medicine and completed his post-graduate training atStanford University . - Kipp Weiskopf, M.D., Ph.D. -
Dr. Weiskopf is a co-founder ofALX Oncology and a Whitehead Fellow at theWhitehead Institute for Biomedical Research . He is a leader in the field of macrophage-directed therapies and he oversees a research laboratory that studies novel macrophage and myeloid immune checkpoints.Dr. Weiskopf is concurrently appointed as a Hematology and Oncology fellow at theDana-Farber Cancer Institute .Dr. Weiskopf is an inventor on 12 U.S. patents and patent applications pertaining to macrophage-directed therapies, including the engineered SIRP variants that underlie the development of ALX148. He is also the recipient of the Churchill Scholarship, theNational Cancer Institute Ruth L. Kirschstein National Research Service Award and the Harold M. Weintraub Graduate Student Award and received first place in theCollegiate Inventors Competition .Dr. Weiskopf holds a B.A. fromAmherst College , anM.Phil . fromUniversity of Cambridge , and an M.D. and Ph.D. fromStanford University .Dr. Weiskopf trained in internal medicine at Brigham and Women’s Hospital.
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on ALX Oncology’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the Company’s clinical pipeline and the expectations regarding the beneficial characteristics, safety, efficacy and therapeutic effects of ALX148. These and other risks are described more fully in ALX Oncology’s filings with the
Investor Contact:Peter Garcia Chief Financial Officer,ALX Oncology (650) 466-7125 Ext. 113 peter@alxoncology.comArgot Partners (212)-600-1902 alx@argotpartners.com Media Contact:Karen Sharma MacDougall (781) 235-3060 alx@macbiocom.com
Source:
2020 GlobeNewswire, Inc., source